Bristol Myers Squibb (CELG-RI) Debt to Equity (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Debt to Equity data on file, last reported at $2.22 in Q1 2026.

• Debt to Equity for Q1 2026 came in at $2.22, down 98.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.22 (down 98.7% YoY), and the FY2025 annual result was $2.44, down 26.66% from the prior year.
• Debt to Equity declined to $2.22 in Q1 2026 per CELG-RI's latest filing, from $2.44 in the prior quarter.
• Over five years, Debt to Equity peaked at $910.83 in Q2 2025 and troughed at -$46.49 in Q3 2022.
• A 5-year average of $126.94 and a median of $2.44 in 2025 frame the typical range for Debt to Equity.
• On a YoY basis, Debt to Equity climbed as much as 65455.05% in 2022 and fell as far as 4702.23% in 2022.
• A 5-year view of Debt to Equity shows it stood at -$30.69 in 2022, then grew by 16.19% to -$25.73 in 2023, then surged by 112.94% to $3.33 in 2024, then fell by 26.66% to $2.44 in 2025, then dropped by 9.28% to $2.22 in 2026.
• Business Quant data shows CELG-RI's Debt to Equity at $2.22 in Q1 2026, $2.44 in Q4 2025, and $2.63 in Q3 2025.